Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
European journal of cancer (Oxford, England : 1990).
Times cited: 27
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT